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aortic stenosis (AS).Background Low ﬂow (i.e., reduced stroke volume index [SVi]) can occur with both reduced and preserved LVEF. Low ﬂow is often
associated with low gradient despite severe stenosis and with worse outcomes following surgical aortic valve
replacement. However, there are few data about the impact of low ﬂow on outcomes following TAVR.Methods We retrospectively analyzed the clinical, Doppler-echocardiographic, and outcome data prospectively collected in
639 patients who underwent TAVR for symptomatic severe AS in 2 Canadian centers.Results In this cohort, 334 (52.3%) patients had a low ﬂow (SVi <35 ml/m2) and these patients had increased
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Figure 1
Incidence of 30-Day Mortality According to Flow,
Gradient, and Ejection Fraction Status
NF-HG ¼ normal ﬂow and high gradient; NF-LG¼ normal ﬂow and low gradient;
LF-HG¼ lowﬂowandhighgradient; LF-LG¼ lowﬂowand lowgradient; LF-LG-NEF¼ low
ﬂow, low gradient, and normal ejection fraction; LF-LG-LEF ¼ low ﬂow, low gradient,
and low ejection fraction.
Abbreviations
and Acronyms
AS = aortic stenosis
CI = conﬁdence interval
HG = high gradient
HR = hazard ratio
LEF = low ejection fraction
LF = low ﬂow
LG = low gradient
LV = left ventricle/
ventricular
LVEF = left ventricular
ejection fraction
MG = mean gradient
NEF = normal ejection
fraction
NF = normal ﬂow
OR = odds ratio
SVi = stroke volume index
TAVR = transcatheter aortic
valve replacement
JACC Vol. 62, No. 9, 2013 Le Ven et al.
August 27, 2013:782–8 Impact of Low Flow After TAVR
783Furthermore, recent studies reported that the presence of
a low transvalvular gradient prior to procedure is associated
with increased mortality following TAVR, whereas the
analyses with respect to impact of LVEF on post-procedural
outcomes yielded to conﬂicting results (4–7).
The objective of this study was thus to examine the
respective impact of pre-procedural ﬂow (i.e., SVi), LVEF,
and transvalvular gradient on mortality following TAVR.
Methods
We retrospectively analyzed the clinical and Doppler-
echocardiographic data prospectively collected in 775
consecutive patients who underwent TAVR with a balloon-
expandable valve for symptomatic severe AS between
January 2005 and April 2012 at the Québec Heart and Lung
Institute and St. Paul’s Hospital. We excluded patients who
had: 1) “valve-in-valve” procedure; 2) TAVR for other indi-
cation than severe AS; and 3) incomplete pre-procedural
Doppler-echocardiographic data. Finally, 639 patients
(82.5%) were included in the study. The study protocol was
performed in accordance with the institutional ethics
committees of each center, and all patients gave informed
written consent for the procedures and the research study.
Doppler echocardiography. Parameters of LV and aortic
valve function were measured by Doppler echocardiography
prior to the procedure, as previously described (8). Stroke
volume was measured by pulsed wave Doppler in the LV
outﬂow tract and was indexed for body surface area (SVi). The
patients were ﬁrst separated into 4 groups according to their
SVi and mean gradient: 1) NF (SVi >35 ml/m2) and HG
(40 mm Hg) (NF-HG); 2) NF and LG (<40 mm Hg)
(NF-LG); 3) LF (SVi <35 ml/m2) and HG (LF-HG); and
4) LF and LG (LF-LG). The LF-LG group was then further
separated into 2 groups according to LVEF, that is, classical
LF-LG with low LVEF (<50%) (LF-LG-low ejection
fraction [LEF]) and paradoxical LF-LG with preserved
LVEF (50%) (LF-LG-normal EF [NEF]).
Study endpoints. The primary endpoint of this study was
all-cause mortality and the secondary endpoints were
cardiovascular mortality and 30-day mortality deﬁned
according to the Valve Academic Research Consortium-2
recommendations (9).
Statistical analysis. Continuous variables were tested for
distribution normality with the Shapiro-Wilk test and
expressed as mean  SD or median and interquartile range.
Because EuroSCORE and Society of Thoracic Surgeons score
were not normally distributed, a natural log transformation
was used for these variables. Differences between groups were
assessed using analysis of variance for continuous variables
with subsequent Tukey HSD pairwise comparisons, and the
chi-square test or Fisher exact test for categorical variables as
appropriate. Survival curves were presented as Kaplan-Meier
curves, and the log-rank test was used for comparison
between groups. The effect of the clinical and Doppler
echocardiographic variables on survival was assessed with Coxproportional hazards regression
models for cumulative all-cause
and cardiovascular mortality and
with backward stepwise logistic
regression models for 30-day
mortality. Clinically relevant vari-
ables with a p value 0.1 on
individual analysis were included
in the multivariable models. Age
was forced into the models. A
p value 0.05 was considered
statistically signiﬁcant.Results
Table 1 shows the comparison of
the patients’ baseline character-
istics between the 5 study groups.
Impact of ﬂow, LVEF, and
gradient on 30-day mortality.
Patients with LF had higher
30-day mortality compared with
those in the NF group (38 of
334 [11%] vs. 18 of 305 [6%],
p ¼ 0.01) (Fig. 1). Among patients with LF-LG, 30-day
mortality was not statistically different (p ¼ 0.5) between
those with NEF (9%) and those with LEF (12%) (Fig. 1).
The independent predictors of 30-day mortality were male
gender (odds ratio [OR]: 1.90 [95% conﬁdence interval (CI):
1.07 to 3.46], p ¼ 0.03), diabetes (OR: 2.2 [95% CI: 1.11 to
Table 1 Baseline Characteristics
Variables
All Patients
(n ¼ 639)
NF-HG
(n ¼ 195)
NF-LG
(n ¼ 110)
LF-HG
(n ¼ 158)
LF-LG-NEF
(n ¼ 86)
LF-LG-LEF
(n ¼ 90) p Value
Clinical data
Age, yrs 81  8 82  8 80  6 81  8 81  8 80  8 0.12
Male, % 311 (48.7) 87 (44.6) 53 (48.2) 78 (49.4) 34 (39.5) 59 (65.6)*yzx 0.005
BMI, kg/m2 26.2  5.5 26.0  5.1 26.2  5.3 26.9  6.2 25.3  4.8 26.3  5.8 0.25
Diabetes, % 190 (29.7) 49 (25.1) 40 (36.4) 46 (29.1) 23 (26.7) 32 (35.6) 0.19
Dyslipidemia, % 446 (69.8) 122 (62.6) 80 (72.7) 111 (70.3) 56 (65.1) 77 (85.6)*yzx 0.001
Hypertension, % 505 (79.0) 153 (78.5) 96 (87.3) 118 (74.7) 65 (75.6) 73 (81.1) 0.1
Smoker status, % 86 (13.5) 22 (11.3) 21 (19.1) 18 (11.4) 12 (14.0) 13 (14.4) 0.34
NYHA functional class III 540 (84.5) 160 (82.1) 91 (82.7) 135 (85.4) 74 (86.0) 80 (88.9) 0.59
Permanent atrial
ﬁbrillation/ﬂutter, %
236 (36.9) 47 (24.1) 35 (31.8) 65 (41.1)* 47 (54.7)*yz 42 (46.7)*y <0.001
Coronary artery disease, % 403 (63.1) 100 (51.3) 74 (67.3)* 110 (69.6)* 53 (61.6) 66 (73.3)* <0.001
Previous myocardial
infarction, %
257 (40.2) 58 (29.7) 49 (44.6)* 75 (47.5)* 30 (34.9) 45 (50.0)*x 0.001
Previous PCI, % 169 (26.4) 41 (21.0) 38 (34.5)* 36 (22.8)y 22 (25.6) 32 (35.6)*z 0.02
Previous coronary artery
bypass graft, %
217 (34.0) 48 (24.6) 44 (40.0)* 59 (37.3)* 27 (31.4) 39 (43.3)* 0.007
Cerebrovascular disease, % 108 (16.9) 28 (14.4) 19 (17.3) 29 (18.4) 12 (14.0) 20 (22.2) 0.49
Peripheral artery disease, % 204 (31.9) 59 (30.3) 43 (39.1) 39 (24.7) 29 (33.7) 34 (37.8) 0.08
COPD, % 191 (29.9) 50 (25.6) 38 (34.5) 42 (26.6) 31 (36.0) 30 (33.3) 0.2
Estimated GFR, ml/min 55.0  22.8 55.0  22.6 53.2  20.9 56.9  21.9 57.1 25.8 51.8  23.9 0.37
Transapical approach, % 273 (42.7) 70 (35.9) 52 (47.3) 65 (41.1) 42 (48.8) 44 (48.9) 0.11
Logistic EuroSCORE, % 21.7 (12.5–35.8) 20.0 (12.9–31.0) 24.3 (16.5) 23.0 (11.9–37.5) 18.4 (9.6–32.3) 31.8 (18.4–49)*yzx <0.001
STS score, % 7.0 (4.7–10.4) 6.9 (4.5–10.1) 7.5 (4.8–10.3) 6.7 (4.4–10.2) 7.3 (4.3–10.4) 7.95 (5.9–12.2) 0.09
Doppler echocardiographic data
LVEF, % 54  14 61  9 54  14* 55  13* 60  7yz 32  10*yzx <0.001
Mean gradient, mm Hg 43  16 56  14 32  5* 51  11*y 31  6*z 27  8*yz <0.001
Aortic valve area, cm2 0.63  0.16 0.62  0.14 0.76  0.15* 0.52  0.13*y 0.65  0.14yz 0.67  0.15*yz <0.001
Moderate-severe AR 46 (7.2) 15 (7.7) 10 (9.1) 11 (7.0) 6 (7.0) 4 (4.4) 0.77
Moderate-severe MR 175 (27.4) 52 (26.7) 25 (22.7) 55 (34.8)y 15 (17.4)z 28 (31.1)x 0.03
Stroke volume index, ml/m2 35  9 43  7 41  5* 29  4*y 29  5*y 27  5*yz <0.001
Pulmonary hypertension, % 154 (24.1) 35 (17.9) 29 (26.4) 45 (28.5) 20 (23.3) 25 (27.8) 0.14
Values are mean  SD, n (%), or median (interquartile range). *p < 0.05 versus NF-HG. yp < 0.05 versus NF-LG. zp < 0.05 versus LF-HG. xp < 0.05 versus LF-LG-NEF.
AR ¼ aortic regurgitation; BMI ¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; GFR ¼ glomerular ﬁltration rate;
LF-HG ¼ low ﬂow and high gradient; LF-LG ¼ low ﬂow and low gradient; LF-LG-LEF ¼ low ﬂow, low gradient, and low ejection fraction; LF-LG-NEF ¼ low ﬂow, low gradient, and normal ejection fraction; LVEF ¼
left ventricular ejection fraction; MR ¼ mitral regurgitation; NF-HG ¼ normal ﬂow and high gradient; NF-LG ¼ normal ﬂow and low gradient; PCI ¼ percutaneous coronary intervention; STS ¼ Society of
Thoracic Surgeons.
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7844.73], p ¼ 0.032), estimated glomerular ﬁltration rate (OR:
1.14 [95% CI: 1.01 to 1.30] per 10 ml/min decrease, p ¼
0.037), pulmonary hypertension (OR: 2.26 [95% CI: 1.25 to
4.04], p ¼ 0.008), and SVi <35 ml/m2 (OR: 1.94 [95% CI:
1.08 to 3.59], p ¼ 0.026).
Impact of ﬂow, LVEF, and gradient on cumulative
mortality. Overall, there were 207 deaths during a median
follow-up of 12 (interquartile range: 1.5 to 24) months and
125 were of cardiovascular cause. Patients with LF had
increased all-cause mortality (hazard ratio [HR]: 1.48 [95%
CI: 1.13 to 1.97], p ¼ 0.005) and cardiovascular mortality
(HR: 1.57 [95% CI: 1.10 to 2.27], p ¼ 0.01) compared with
those with NF (Fig. 2). Mortality was also increased in
patients with LEF compared with those with NEF (all-cause
mortality HR: 1.61 [95% CI: 1.19 to 2.14], p ¼ 0.002;
cardiovascular mortalityHR: 1.73 [95%CI: 1.18 to 2.49], p¼
0.005) and in patients with LG compared with those with
HG (all-cause mortalityHR: 1.45 [95%CI: 1.10 to 1.91], p¼0.008; cardiovascular mortality HR: 1.55 [95% CI: 1.09 to
2.22], p ¼ 0.016).
Patients in NF-HG, LF-HG, and NF-LG groups had
similar outcomes (all-cause mortality p¼ 0.18; cardiovascular
mortality p ¼ 0.21), whereas all-cause mortality was signiﬁ-
cantly higher in LF-LG group compared with NF-HG (HR:
1.96 [95%CI: 1.36 to 2.83], p¼ 0.0003), NF-LG (HR: 1.61
[95% CI: 1.06 to 2.48], p ¼ 0.02), and LF-HG (HR: 1.52
[95% CI: 1.06 to 2.19], p ¼ 0.02) groups (Fig. 3). Cardio-
vascular mortality was also increased in the LF-LG group
compared with the NF-HG group (HR: 2.18 [95% CI: 1.36
to 3.53], p¼ 0.001). After further dichotomization of the LF-
LG group according to LVEF, no signiﬁcant difference was
observed between LF-LG-NEF and LF-LG-LEF sub-
groups with respect to all-cause (p ¼ 0.21) or cardiovascular
(p ¼ 0.33) mortality (Fig. 4).
The predictors of all-cause and cardiovascular mortality
are shown in Tables 2 and 3, respectively. In multivariable
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Figure 2 Kaplan-Meier Curves According to Stroke Volume Indexed to Body Surface Area
Curves for all-cause mortality (A) and cardiovascular mortality (B). Abbreviations as in Figure 1.
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785analysis, SVi was an independent predictor of both all-cause
mortality (HR: 1.27 [95% CI: 1.04 to 1.55] per 10 ml/m2
decrease, p ¼ 0.016) and cardiovascular mortality (HR: 1.29
[95% CI: 1.01 to 1.66] per 10 ml/m2 decrease, p ¼ 0.04).
Although they were signiﬁcant predictors in univariable
analysis, LVEF and mean gradient were not independent
predictors in multivariable analysis (Tables 2 and 3).
Discussion
Themainﬁndings of this study are: 1) about half of the patients
undergoingTAVRare in LF state; 2) LF but not lowLVEFor
LG is an independent predictor of cumulative all-cause and
cardiovascular mortality as well as 30-day mortality followingLF-HG
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compared with those with classical LF-LG-LEF.
Numerous studies have reported that low LVEF is
a powerful independent risk factor for increased early and
late mortality following surgical aortic valve replacement,
and this factor is included in the operative risk scores
(10,11). In the context of TAVR, some studies reported an
association between low baseline LVEF and increased
mortality (4,7) but others did not (5,6). In the PARTNER-I
(Placement of AoRTic TraNscathetER Valves) trial (5),
reduced LVEF was not a predictor of mortality in both the
surgical aortic valve replacement and TAVR arms. However,0
25
50
Months
195 135 112 75 57
110 76 60 37 31
158 107 88 63 53
176 101 78 51 35
LF-LG
NF-LG
LF-HG
NF-HG
p = 0.01
*
LF-HG
NF-HG
NF-LG
LF-LG
Patients at risk
)
%(
ytil
atr
o
m
r
al
ucs
a
v
oidr
a
C
0 42216 18
B
d According to Flow and Gradient Levels
HG. {p < 0.05 versus NF-LG; xp < 0.05 versus LF-HG. Abbreviations as in Figure 1.
0
0
4221
Months
25
50
LF-HG
NF-HG
NF-LG
LF-LG-NEF
LF-LG-LEF
LF-HG
NF-HG
NF-LG
LF-LG-NEF
LF-LG-LEF
112 75 57
60 37 31
88 63 53
44 28 17
195 135
110 76
158 107
86 55
90 46 34 23 18
Patients at risk
*¶§
*p = 0.002)
%(
 ytil
atr
o
m
 es
u
ac
-ll
A
186
0
25
50
0
NF-LG
LF-HG
NF-HG
LF-LG-NEF
LF-LG-LEF
p = 0.01
*¶§
*
LF-HG
NF-HG
NF-LG
LF-LG-NEF
LF-LG-LEF
112 75 57
60 37 31
88 63 53
44 28 17
195 135
110 76
158 107
86 55
90 46 34 23 18
Patients at risk
)
%(
 ytil
atr
o
m
 r
al
ucs
a
v
oidr
a
C
4221
Months
186
A B
Figure 4 Kaplan-Meier Curves Analysis After Further Dichotomization of LF-LG Group According to Left Ventricular Ejection Fraction
Curves for overall survival (A) and cardiovascular survival (B). *p < 0.05 versus NF-HG. {p < 0.05 versus NF-LG; xp < 0.05 versus LF-HG. Abbreviations as in Figure 1.
Le Ven et al. JACC Vol. 62, No. 9, 2013
Impact of Low Flow After TAVR August 27, 2013:782–8
786patients with a LVEF <20% were excluded from this trial.
In the present study, low LVEF was associated with
increased mortality in univariable analysis but after adjust-
ment for other risk factors including SVi, this association
was no longer signiﬁcant. On the other hand, reduced SViTable 2 Predictors of All-Cause Mortality
Variables
Univariable
HR (95% CI)
Age (per 1-yr increase) 1.01 (0.99–1.03)
Male 1.67 (1.27–2.21)
BMI (per 10 kg/m2 decrease) 1.34 (1.01–1.79)
Diabetes 0.85 (0.62–1.16)
Dyslipidemia 0.83 (0.63–1.12)
Hypertension 0.88 (0.65–1.22)
Smoking status 1.20 (0.82–1.72)
NYHA functional class III 1.37 (0.90–2.17)
Permanent atrial ﬁbrillation/ﬂutter 1.77 (1.34–2.33)
Coronary artery disease 1.34 (0.99–1.81)
Previous myocardial infarction 1.07 (0.81–1.42)
Previous PCI 0.98 (0.72–1.33)
Previous coronary artery bypass graft 1.00 (0.75–1.33)
Cerebrovascular disease 1.22 (0.85–1.71)
Peripheral artery disease 1.23 (0.93–1.63)
COPD 1.41 (1.05–1.88)
Estimated GFR (per 10 ml/min decrease) 1.14 (1.07–1.22)
Logistic EuroSCORE (per 1 U increase) 1.01 (1.00–1.02)
STS score (per 1 U increase) 1.06 (1.04–1.09)
Transapical approach 1.23 (0.94–1.62)
LVEF (per 10% decrease) 1.18 (1.08–1.29)
Mean gradient (per 10 mm Hg decrease) 1.16 (1.05–1.27)
Aortic valve area (per 0.1 cm2 increase) 1.03 (0.94–1.12)
AR moderate or severe 1.37 (0.80–2.19)
MR moderate or severe 1.07 (0.79–1.43)
Stroke volume index (per 10 ml/m2 decrease) 1.40 (1.18–1.67)
Pulmonary hypertension 1.54 (1.14–2.04)
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.was independently associated with increased early and late
mortality. LVEF may underestimate the extent of myocar-
dial systolic dysfunction in presence of concentric remodel-
ing, such as generally observed in patients with severe AS,
whereas SVi is a direct measure of the efﬁciency of theAnalysis Multivariable Analysis
p Value HR (95% CI) p Value
0.28 1.01 (0.99–1.03) 0.38
<0.001 1.49 (1.11–2.0) 0.008
0.04 1.49 (1.09–2.05) 0.01
0.32 d d
0.23 d d
0.43 d d
0.34 d d
0.14 d d
<0.001 1.51 (1.13–2.01) 0.005
0.051 1.14 (0.84–1.57) 0.42
0.64 d d
0.91 d d
0.99 d d
0.27 d d
0.15 d d
0.02 1.53 (1.12–2.06) 0.008
<0.001 1.14 (1.07–1.22) <0.001
0.002 d d
<0.001 d d
0.14 d d
<0.001 1.03 (0.92–1.14) 0.62
0.002 1.05 (0.95–1.17) 0.33
0.57 d d
0.23 d d
0.66 d d
<0.001 1.27 (1.04–1.55) 0.016
0.005 0.84 (0.63–1.23) 0.28
Table 3 Predictors of Cardiovascular Mortality
Variables
Univariable Analysis Multivariable Model
HR (95% CI) p Value HR (95% CI) p Value
Age (per 1-yr increase) 1.01 (0.99–1.03) 0.42 1.01 (0.99–1.04) 0.36
Male 1.52 (1.06–2.17) 0.02 1.48 (1.03–2.16) 0.04
BMI (per 10 kg/m2 decrease) 1.01 (0.72–1.41) 0.99 d d
Diabetes 0.80 (0.52–1.98) 0.29 d d
Dyslipidemia 1.01 (0.69–1.50) 0.98 d d
Hypertension 1.17 (0.76–1.87) 0.48 d d
Current smokers 1.34 (0.82–2.09) 0.23 d d
NYHA functional class III 2.22 (1.19–4.72) 0.01 1.75 (0.92–3.76) 0.09
Permanent atrial ﬁbrillation/ﬂutter 1.87 (1.31–2.67) <0.001 1.50 (1.03–2.17) 0.04
Coronary artery disease 1.22 (0.84–1.80) 0.30 d d
Previous myocardial infarction 1.19 (0.83–1.71) 0.34 d d
Previous PCI 1.05 (0.71–1.50) 0.80 d d
Previous coronary artery bypass graft 0.98 (0.67–1.42) 0.92 d d
Cerebrovascular disease 1.36 (0.86–2.07) 0.18 d d
Peripheral artery disease 1.35 (0.94–1.93) 0.11 d d
COPD 1.27 (0.87–1.83) 0.22 d d
Estimated GFR (per 10 ml/min decrease) 1.21 (1.11–1.32) <0.001 1.16 (1.07–1.27) <0.001
Logistical EuroSCORE (per 1 U increase) 1.02 (1.00–1.03) 0.0003 d d
STS score (per 1 U increase) 1.07 (1.04–1.10) 0.0001 d d
Transapical approach 1.40 (0.98–1.99) 0.0645 1.35 (0.93–1.97) 0.11
LVEF (per 10% decrease) 1.20 (1.07–1.34) 0.002 1.08 (0.84–1.16) 0.88
Mean gradient (per 10 mm Hg decrease) 1.24 (1.10–1.41) 0.0005 1.13 (0.98–1.30) 0.09
Aortic valve area (per 0.1 cm2 increase) 1.05 (0.93–1.17) 0.45 d d
AR moderate or severe 1.45 (0.74–2.58) 0.26 d d
MR moderate or severe 1.17 (0.79–1.70) 0.42 d d
Stroke volume index (per 10 ml/m2 decrease) 1.51 (1.22–1.89) <0.001 1.29 (1.01–1.66) 0.04
Pulmonary hypertension 1.86 (1.28–2.67) 0.001 1.39 (0.94–2.02) 0.10
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
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and metabolic demand.
Previous studies (2,3) as well as the recent ESC-EACTS
(European Society of Cardiology-European Association for
Cardio-Thoracic Surgery) guidelines (12) proposed a cut-
point value of 35 ml/m2 to deﬁne LF. The present study
corroborates this cut-point in the context of TAVR but also
suggests that the mortality increases continuously with
further reduction in SVi.
Very low pre-operative mean gradient (<20 mm Hg) has
been associated with increased mortality following surgical
aortic valve replacement in patients with classical LF-LG
AS (11). Several studies also reported an association be-
tween low pre-procedural mean gradient (<40 mm Hg) and
increased mortality following TAVR (5,6). However, in the
present study, the association between mean gradient and
mortality was no longer signiﬁcant after adjustment for SVi.
These ﬁndings suggest that the inverse relationship between
baseline gradient and mortality following TAVR is probably,
in large part, due to the presence of LF.
Study limitations. Data were prospectively collected in
consecutive series of patients from 2 large volume centers
and there were no exclusion criteria with regard to low
LVEF or LG. However, the data were retrospectively
queried and there was no Core Laboratory for the analysisof echocardiograms. The multivariable model for 30-day
mortality may be overﬁtted. Doppler-echocardiographic
estimation of SVi may be subject to measurement errors,
particularly in the presence of poor image quality, elliptic
shape of the LV outﬂow tract, or atrial ﬁbrillation (13).Conclusions
LF but not low LVEF or LG is an independent predictor of
early and late mortality in high-risk patients with severe AS
undergoing TAVR. Assessment of SVi should be included
in the risk stratiﬁcation of these patients. Future randomized
studies are needed to assess the impact of therapy in patients
with LF AS.
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